newsfilter
← Latest News
Business Wire·

SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

First High-Potency Human Polyclonal Antibody Therapeutic Specifically Designed with the Potential to Treat Rapidly-Mutating Type A and Type B Influenza Viruses SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immuno